Shionogi & Co Ltd (4507) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

Shionogi & Co Ltd (Shionogi) focuses on the research, development, manufacturing and marketing of pharmaceutical products, diagnostic reagents and medical devices. The companys core pharmaceuticals product business offers drugs for the treatment of disorders in the areas of metabolism, infection, immunity and cancer pain. Shionogi also sells, distributes and provides information about diagnostic products in the fields of infectious diseases, cardiovascular diseases and allergies. The company operates a network of subsidiaries, branches, sales offices manufacturing plants and research laboratories across Japan, China, Taiwan, North America and Europe. Shionogi is headquartered in Osaka, Japan.

Shionogi & Co Ltd (4507) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

it derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 6
List of Figures 7
Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Shionogi & Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Shionogi & Co Ltd, Medical Devices Deals, 2012 to YTD 2018 13
Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deal Details 17
Venture Financing 17
Nemesis Bioscience Raises USD1.8 Million in Seed Funding 17
Partnerships 18
Sage Therapeutics and Shionogi Enter into Co-Development Agreement 18
Kyoto University and Shionogi Enter into Research Agreement 19
DeNA and DeNA Life Science Enter into Research Partnership with Asahi Kasei Pharma and Shionogi 20
PharmaIN Enters into Agreement with Shionogi 21
Shionogi and UMN Pharma Enter into Agreement 22
Clinigen Enters into Agreement with Shionogi 23
Sekisui Chemical, PeptiDream and Shionogi to Form Joint Venture 24
Takeda Pharma and Shionogi Enter into Research Agreement with Sumitomo Dainippon Pharma, Ono Pharma and Mitsubishi Tanabe Pharma 25
FunPep Enters into Research Agreement with Shionogi 27
Shionogi Enters into Research Agreement with NB Health Labs 28
Shionogi Enters into Research Agreement with Nissan Chemical Industries 29
Mundipharma Enters into Distribution Agreement with Shionogi 30
Noven Pharma Enters Into Co-Promotion Agreement With Shionogi For Brisdelle Capsules 31
ViiV Healthcare And Shionogi Enter Into Co-Promotion Agreement For Dolutegravir 32
Shionogi to Enter into Agreement with TB Alliance 33
Kyoto University and Shionogi Enter into R&D Agreement 34
Licensing Agreements 35
Shionogi Enters into Licensing Agreement with Rohto Pharma 35
Shionogi Enters into Licensing Agreement with Hsiri Therapeutics 36
Pharmbio Korea Enters into Licensing Agreement with Shionogi 37
Ophirex Enters into Licensing Agreement with Eli Lilly and Shionogi 38
Duchesnay Receives Rights for Osphena from Shionogi 39
Shionogi Enters into Licensing Agreement with University of Tokushima 40
F. Hoffmann-La Roche Enters into Licensing Agreement with Shionogi 41
Shionogi Enters into Licensing Agreement with PeptiDream 42
Shionogi Enters into Licensing Agreement with FunPep 43
Shionogi Enters into Licensing Agreement with MedImmune 44
Shionogi Enters Into Licensing Agreement With Janssen Pharma 45
Shionogi Enters Into Licensing Agreement With OncoTherapy Science For Cancer Peptide Vaccines 46
Mundipharma Enters Into Licensing Agreement With Shionogi 47
Plethora Solutions Enters Into Commercialization Agreement With Shionogi For PSD502 48
Concordia Pharma And Shionogi Enter Into Licensing Agreement For Ulesfia 49
Dainippon Sumitomo Pharma Enters Into Licensing Agreement With Shionogi For DSP-8153 50
Equity Offering 51
PharmaIN to Raise USD17 Million in Private Placement of Shares 51
Egalet Completes Private Placement Of Shares For US$15 Million 52
Debt Offering 53
Shionogi Announces Public offering of Convertible Bonds Due 2019 for USD168.5 Million 53
Asset Transactions 54
Kyowa Pharma to Acquire 21 Products from Shionogi 54
Pragma Pharma Acquires Keflex from Shionogi 55
Alvogen Acquires Rights Of Naprelan Tablets From Shionogi 56
Concordia Pharma Acquires Rights To Three US Pediatrics From Shionogi 57
ViiV Healthcare Acquires Integrase Inhibitor Portfolio Of Shionogi 58
Merz Pharma Acquires Cuvposa from Shionogi 59
Shionogi & Co Ltd - Key Competitors 60
Shionogi & Co Ltd - Key Employees 61
Shionogi & Co Ltd - Locations And Subsidiaries 64
Head Office 64
Other Locations & Subsidiaries 64
Joint Venture 66
Recent Developments 67
Strategy And Business Planning 67
Apr 23, 2018: Shionogi Announces Establishment Of New Manufacturing Subsidiary In Japan 67
Feb 07, 2017: Shionogi to Announce Corporate Reorganization and Personnel Reassignment 68
Financial Announcements 72
Jul 30, 2018: Shionogi: Financial Results for the First Quarter of Fiscal Year 2018(Consolidated) 72
May 09, 2018: Shionogi : Financial Results for Fiscal Year 2017 73
Feb 05, 2018: Shionogi: Financial Results for the Third Quarter of Fiscal Year 2017(Consolidated) 75
Jul 31, 2017: Shionogi Reports Revenue Of JPY75 Billion In Q1 Fiscal 2018 76
May 10, 2017: Shionogi Reports Revenue Of JPY338.9 Billion In Fiscal 2016 77
Feb 02, 2017: Shionogi Reports Revenue Of JPY256.5 Billion In Third Quarter Ended December 31, 2016 78
Corporate Communications 79
Mar 19, 2018: Shionogi to Announce Executive Appointments 79
Mar 21, 2017: Shionogi to Announce Executive Appointments 80
Product News 81
10/04/2017: Shionogi Presents Positive Clinical Efficacy Trial Results And In Vitro Data On Cefiderocol, At IDWeek 2017 81
06/01/2017: Further Evidence Supports Cefiderocol Activity Against MDR Gram-Negative Pathogens: Data Presented at the American Society for Microbiology Microbe Meeting 83
04/22/2017: Shionogi Presents Results of the First Clinical Efficacy Trial and In Vitro Data on Cefiderocol (S-649266), a Siderophore Cephalosporin 85
04/18/2018: Shionogi to Present New Data on COT-143 at 2018 European Congress of Clinical Microbiology and Infectious Diseases 87
03/23/2017: FDA Approves Symproic (naldemedine) Once-Daily Tablets C-II for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-Cancer Pain 88
01/12/2017: Shionogi Announces Positive Top-Line Results For Cefiderocol Pivotal cUTI Clinical Trial 89
Product Approvals 90
Mar 30, 2017: Symproic (naldemedine) Approved for the Treatment of Opioid-Induced Constipation in Japan 90
Clinical Trials 91
May 30, 2018: Kissei Announces Negative Topline Results from the additional phase III Clinical Trial evaluating KPS-0373 (Development Code) for the Treatment of Spinocerebellar Ataxia 91
Mar 05, 2018: OncoTherapy Science: Announcement of the progress of Phase III clinical study of the cancer-specific peptide vaccine S-588410 92
Sep 28, 2017: Shionogi to Highlight Research on Cefiderocol (S-649266), A Siderophore Cephalosporin at IDWeek 2017 93
Jun 30, 2017: Announcement of milestone payment for the progress of Phase III clinical trial of the cancer-specific peptide vaccine S-588410 95
Apr 17, 2017: Shionogi to Present New Data on Cefiderocol (S-649266), a Siderophore Cephalosporin at the 27th European Congress of Clinical Microbiology and Infectious Diseases 96
Other Significant Developments 98
Sep 12, 2018: Shionogi to announce corporate reorganization 98
Feb 28, 2018: Shionogi to Announce Corporate Reorganizations 99
Mar 22, 2017: PeptiDream Announces 1st Milestone from Macrocyclic Peptide Drug Discovery Alliance with Shionogi 100
Appendix 101
Methodology 101
About GlobalData 101
Contact Us 101
Disclaimer 101

List Of Tables


Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Shionogi & Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Shionogi & Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 11
Shionogi & Co Ltd, Medical Devices Deals, 2012 to YTD 2018 13
Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
Nemesis Bioscience Raises USD1.8 Million in Seed Funding 17
Sage Therapeutics and Shionogi Enter into Co-Development Agreement 18
Kyoto University and Shionogi Enter into Research Agreement 19
DeNA and DeNA Life Science Enter into Research Partnership with Asahi Kasei Pharma and Shionogi 20
PharmaIN Enters into Agreement with Shionogi 21
Shionogi and UMN Pharma Enter into Agreement 22
Clinigen Enters into Agreement with Shionogi 23
Sekisui Chemical, PeptiDream and Shionogi to Form Joint Venture 24
Takeda Pharma and Shionogi Enter into Research Agreement with Sumitomo Dainippon Pharma, Ono Pharma and Mitsubishi Tanabe Pharma 25
FunPep Enters into Research Agreement with Shionogi 27
Shionogi Enters into Research Agreement with NB Health Labs 28
Shionogi Enters into Research Agreement with Nissan Chemical Industries 29
Mundipharma Enters into Distribution Agreement with Shionogi 30
Noven Pharma Enters Into Co-Promotion Agreement With Shionogi For Brisdelle Capsules 31
ViiV Healthcare And Shionogi Enter Into Co-Promotion Agreement For Dolutegravir 32
Shionogi to Enter into Agreement with TB Alliance 33
Kyoto University and Shionogi Enter into R&D Agreement 34
Shionogi Enters into Licensing Agreement with Rohto Pharma 35
Shionogi Enters into Licensing Agreement with Hsiri Therapeutics 36
Pharmbio Korea Enters into Licensing Agreement with Shionogi 37
Ophirex Enters into Licensing Agreement with Eli Lilly and Shionogi 38
Duchesnay Receives Rights for Osphena from Shionogi 39
Shionogi Enters into Licensing Agreement with University of Tokushima 40
F. Hoffmann-La Roche Enters into Licensing Agreement with Shionogi 41
Shionogi Enters into Licensing Agreement with PeptiDream 42
Shionogi Enters into Licensing Agreement with FunPep 43
Shionogi Enters into Licensing Agreement with MedImmune 44
Shionogi Enters Into Licensing Agreement With Janssen Pharma 45
Shionogi Enters Into Licensing Agreement With OncoTherapy Science For Cancer Peptide Vaccines 46
Mundipharma Enters Into Licensing Agreement With Shionogi 47
Plethora Solutions Enters Into Commercialization Agreement With Shionogi For PSD502 48
Concordia Pharma And Shionogi Enter Into Licensing Agreement For Ulesfia 49
Dainippon Sumitomo Pharma Enters Into Licensing Agreement With Shionogi For DSP-8153 50
PharmaIN to Raise USD17 Million in Private Placement of Shares 51
Egalet Completes Private Placement Of Shares For US$15 Million 52
Shionogi Announces Public offering of Convertible Bonds Due 2019 for USD168.5 Million 53
Kyowa Pharma to Acquire 21 Products from Shionogi 54
Pragma Pharma Acquires Keflex from Shionogi 55
Alvogen Acquires Rights Of Naprelan Tablets From Shionogi 56
Concordia Pharma Acquires Rights To Three US Pediatrics From Shionogi 57
ViiV Healthcare Acquires Integrase Inhibitor Portfolio Of Shionogi 58
Merz Pharma Acquires Cuvposa from Shionogi 59
Shionogi & Co Ltd, Key Competitors 60
Shionogi & Co Ltd, Key Employees 61
Shionogi & Co Ltd, Other Locations 64
Shionogi & Co Ltd, Subsidiaries 65
Shionogi & Co Ltd, Joint Venture 66

List Of Figures


Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9
Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Shionogi & Co Ltd, Medical Devices Deals, 2012 to YTD 2018 13

Shionogi and Co Ltd (4507) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Shionogi & Co Ltd (Shionogi) focuses on the research, development, manufacturing and marketing of pharmaceutical products, diagnostic reagents and medical devices. The companys core pharmaceuticals product business offers drugs for

USD 250 View Report

Shionogi and Co., Ltd. - Mergers and Acquisitions (MandA), Partnerships and Alliances and Investment Report

Shionogi & Co., Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment ReportThe Shionogi & Co., Ltd. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes

USD 350 View Report

Hyundai Engineering & Construction Co Ltd (000720) - Financial and Strategic SWOT Analysis Review

Hyundai Engineering & Construction Co Ltd (000720) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has

USD 125 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available